Signaturefd LLC Decreases Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Signaturefd LLC cut its stake in Moderna, Inc. (NASDAQ:MRNA) by 53.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,083 shares of the company’s stock after selling 3,605 shares during the period. Signaturefd LLC’s holdings in Moderna were worth $206,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Raymond James & Associates raised its stake in shares of Moderna by 19.7% during the 3rd quarter. Raymond James & Associates now owns 162,074 shares of the company’s stock worth $10,831,000 after buying an additional 26,657 shares during the last quarter. Blue Trust Inc. raised its position in Moderna by 365.6% during the third quarter. Blue Trust Inc. now owns 731 shares of the company’s stock worth $49,000 after acquiring an additional 574 shares during the last quarter. V Square Quantitative Management LLC lifted its holdings in shares of Moderna by 101.0% in the third quarter. V Square Quantitative Management LLC now owns 5,649 shares of the company’s stock valued at $378,000 after purchasing an additional 2,838 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd grew its position in shares of Moderna by 2.2% in the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 34,206 shares of the company’s stock valued at $2,286,000 after purchasing an additional 746 shares during the last quarter. Finally, nVerses Capital LLC purchased a new position in shares of Moderna during the 3rd quarter worth approximately $301,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Stock Up 0.5 %

Shares of NASDAQ:MRNA opened at $53.09 on Monday. The stock has a 50-day simple moving average of $67.68 and a 200-day simple moving average of $102.77. The stock has a market capitalization of $20.41 billion, a P/E ratio of -3.45 and a beta of 1.66. Moderna, Inc. has a 1 year low of $52.26 and a 1 year high of $170.47. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.47) by $0.14. The company had revenue of $241.00 million during the quarter, compared to the consensus estimate of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. Moderna’s revenue for the quarter was down 29.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($3.62) earnings per share. Equities analysts forecast that Moderna, Inc. will post -9.94 earnings per share for the current year.

Insider Buying and Selling at Moderna

In other news, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $119.96, for a total value of $1,799,400.00. Following the completion of the sale, the director now owns 2,224,015 shares in the company, valued at approximately $266,792,839.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $119.96, for a total transaction of $1,799,400.00. Following the completion of the transaction, the director now owns 2,224,015 shares in the company, valued at $266,792,839.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 18,184 shares of company stock valued at $2,037,931 over the last three months. 15.70% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

MRNA has been the topic of a number of recent research reports. UBS Group reduced their target price on Moderna from $140.00 to $108.00 and set a “buy” rating on the stock in a research note on Thursday. Deutsche Bank Aktiengesellschaft raised Moderna from a “sell” rating to a “hold” rating and decreased their price objective for the company from $85.00 to $80.00 in a research note on Wednesday, August 7th. Oppenheimer lowered shares of Moderna from an “outperform” rating to a “market perform” rating in a report on Friday, September 13th. HSBC upgraded shares of Moderna from a “reduce” rating to a “hold” rating and set a $82.00 price target for the company in a report on Wednesday, August 28th. Finally, Barclays reduced their price objective on shares of Moderna from $155.00 to $125.00 and set an “overweight” rating on the stock in a research note on Monday, September 16th. Two research analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Moderna presently has an average rating of “Hold” and a consensus price target of $94.65.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.